The French-language network ARTE has released a documentary exploring the medical and ethical implications of cloning three decades after the birth of Dolly [1].

This retrospective arrives as scientists continue to weigh the potential for therapeutic breakthroughs against the profound moral questions raised by creating genetic duplicates. The film assesses whether the early promises of the cloning revolution have materialized into viable medical treatments.

Dolly, a Scottish Blackface sheep, became the first mammal cloned from an adult cell in 1996 [1], [2]. This breakthrough shifted the scientific understanding of cellular development and sparked a global conversation about the limits of biological engineering. The documentary said the event marked the beginning of a new era in genetic research [3].

The film traces the evolution of the technology beyond livestock. It highlights subsequent milestones in the field, including the birth of CopyCat in 2001, which was the first cloned pet cat [3]. These advancements shifted cloning from a purely academic pursuit to a commercial possibility for pet owners, a transition that remains a point of contention among bioethicists.

Directed by Kirsten Esch, the production asks what medical perspectives cloning can offer today [3]. The narrative examines the tension between the desire to cure degenerative diseases and the risk of unregulated human cloning. The documentary is currently streaming on the ARTE website and will remain available online until July 5, 2027 [4].

Experts in the film said the bio-ethical debates have persisted since the late 1990s. While the ability to clone animals has improved, the application of these techniques to human medicine requires navigating complex legal, and moral landscapes. The documentary serves as a ledger of what has been achieved and what remains prohibited in the pursuit of genetic replication [3].

“Dolly is become the first animal cloned from a cell taken from an adult.”

The transition of cloning from a scientific miracle in 1996 to a commercial service for pets reflects a broader trend of biotechnological normalization. However, the enduring ethical debates highlighted by ARTE suggest that while the technical barriers to cloning are falling, the societal and moral consensus on its application to humans remains stalled.